ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 171 filers reported holding ASCENDIS PHARMA A/S in Q4 2021. The put-call ratio across all filers is 1.59 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $672,054 | +18.3% | 7,177 | +12.8% | 0.04% | +21.6% |
| Q2 2023 | $567,897 | -8.9% | 6,363 | +9.4% | 0.04% | -14.0% |
| Q1 2023 | $623,591 | -7.7% | 5,816 | +5.2% | 0.04% | -15.7% |
| Q4 2022 | $675,256 | +21.4% | 5,529 | +2.5% | 0.05% | +10.9% |
| Q3 2022 | $556,000 | +11.4% | 5,393 | +0.4% | 0.05% | -8.0% |
| Q2 2022 | $499,000 | -20.8% | 5,369 | 0.0% | 0.05% | -7.4% |
| Q1 2022 | $630,000 | -25.0% | 5,369 | -14.1% | 0.05% | -21.7% |
| Q4 2021 | $840,000 | +9.8% | 6,251 | +30.1% | 0.07% | +9.5% |
| Q3 2021 | $765,000 | +21.2% | 4,804 | 0.0% | 0.06% | 0.0% |
| Q2 2021 | $631,000 | +14.7% | 4,804 | +12.4% | 0.06% | +6.8% |
| Q1 2021 | $550,000 | +1.1% | 4,275 | +30.9% | 0.06% | -11.9% |
| Q4 2020 | $544,000 | +30.1% | 3,267 | +20.6% | 0.07% | +11.7% |
| Q3 2020 | $418,000 | +11.5% | 2,710 | +6.7% | 0.06% | +1.7% |
| Q2 2020 | $375,000 | +83.8% | 2,540 | +39.6% | 0.06% | +47.5% |
| Q1 2020 | $204,000 | – | 1,820 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
| Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
| Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
| Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
| Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
| Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
| Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
| Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
| Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
| Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |